Morinaga Milk's New Probiotic Strain, Bifidobacterium breve A1, May Prevent Onset of Alzheimer's Disease
Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading Japanese dairy product company, today announced the results of a new study investigating the preventive effects of its new probiotic strain Bifidobacterium breve A1 on a model of Alzheimer’s disease. Researchers found that B. breve A1 improved spatial recognition capability, as well as learning and memory capabilities, in cognitively deficient mice, indicating it could play an important role in preventing the onset of Alzheimer’s Disease in humans.1
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180320005052/en/
(Fig. 1) Effects of B. Breve A1 in improving spatial recognition, learning and memory capabilities (Graphic: Business Wire)
The number of patients affected by dementia is increasing worldwide. One report estimates there were 46.8 million people worldwide living with dementia in 2015 and projects this number will reach 131.5 million by 2050.2 Alzheimer’s disease accounts for a large proportion of dementia cases. Like many chronic diseases, Alzheimer’s develops slowly for several decades before the onset of symptoms, even though deterioration in the brain begins in the early stages. Once the disease has developed, it is difficult to reverse it or even halt its progression; therefore, finding effective countermeasures to prevent the disease’s onset is a top priority for researchers.
The “gut‒brain axis,” which is the functional linkage between the brain and gut microbiota, has attracted attention worldwide. Because probiotics are known to have beneficial effects on gut microbiota, they are a promising treatment for brain health. Indeed, both bifidobacteria and lactobacillus have shown beneficial effects on anxiety and depression.
Building on this research, Morinaga Milk investigated the ability of probiotics to prevent the progression of Alzheimer’s disease in collaboration with Professor Keiko Abe from The University of Tokyo and Kanagawa Institute of Industrial Science and Technology. The study, published in the journal Scientific Reports, revealed the potential of B. breve A1 to prevent the onset of Alzheimer’s disease.
Mice were injected with amyloid β — the substance presumed to cause Alzheimer’s disease — in order to induce cognitive dysfunction in a model of Alzheimer’s disease. Mice in the active treatment group were administered B. breve A1 (1 × 109 per day) orally for 10 days (B. breve A1 group). Mice in the control group were given either saline (saline group) or a cholinesterase inhibitor, a medication prescribed for dementia (positive control group). Cognitive function was evaluated by a Y maze test and a passive avoidance test.
Y maze Behavioral Test Confirms Improvement of Spatial Recognition Capability
“Spontaneous alternation” refers to the tendency of normal mice to choose a different path when navigating a maze than the last one chosen, indicating they remember what paths they have already tried. In this study, amyloid β injected mice given saline showed a remarkable reduction in spontaneous alternation rate in the Y maze test compared to normal mice. However, the B. breve A1 group showed a significant improvement in spontaneous alternation rate compared to the saline group. These results indicate that B. breve A1 improves spatial recognition capability (Fig. 1, left).
Passive Avoidance Behavioral Test Reveals Improvement in Learning and Memory Capability
During the passive avoidance test, mice need to learn to avoid a negative stimulus by staying away from a certain area. If they do so successfully, it indicates they remember the negative experience. Similar to the Y maze behavioral test, mice in the B. breve A1 group stayed longer in the area without a negative stimulus compared to the saline group. This result indicates that B. breve A1 improves learning and memory capabilities (Fig. 1, right).
B. breve A1 Nearly as Effective as Common Alzheimer’s Drug
The improvements in both the Y maze test and the passive avoidance test were similar in magnitude to those observed in the positive control group treated with a cholinesterase inhibitor, a medication commonly prescribed for Alzheimer’s disease, indicating that B. breve A1 has similar potential to improve amyloid-induced cognitive impairment.
Hippocampus Gene Expression is Key Behind Mechanism of Action
Morinaga Milk focused on the hippocampus, the area of the brain associated with memory and learning capabilities, by performing comprehensive gene expression analysis in the hippocampus of the mice. The researchers found the expression of many genes was altered; particularly, gene groups associated with immunological reactions and inflammation were changed, causing immunological abnormalities and excessive inflammation in the impaired mice ingesting saline. In contrast, the expression of the majority of these genes remained normal in impaired mice ingesting B. breve A1 (Fig. 2).
These findings led Dr. Jin-zhong Xiao, General Manager of Morinaga Milk’s Next Generation Science Institute, to state that “Intake of B. breve A1 suppressed excessive immunological reactions and inflammation in the brains of the mice and improved cognitive function.” He went on to add, “Chronic inflammation of the brain is characteristic of Alzheimer’s disease. B. breve A1’s ability to suppress inflammation in the hippocampus is the key behind its ability to prevent progression of the disease.” The company plans to continue to research the effects of B. breve A1 on human subjects to further explore its therapeutic potential for preventing Alzheimer’s disease onset.
About Morinaga Milk
Morinaga Milk Industry Co., Ltd. is one of the leading dairy product companies in Japan. Morinaga Milk started research on bifidobacteria in the 1960s, inspired by the fact that bifidobacteria are the predominant bacteria residing in the intestines of breast-fed infants. In 1969, Morinaga Milk isolated its flagship strain Bifidobacterium longum BB536 from an infant. Morinaga Milk excels in innovative technology and offers various dairy products and other beneficial functional ingredients to customers around the world.
|1.||Y. Kobayashi et al. Therapeutic potential of Bifidobacterium breve strain A1 for preventing cognitive impairment in Alzheimer’s disease. Scientific Reports 7(1). Dec. 2017.|
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Amazon Studios Greenlights Utopia, Signs Gillian Flynn to Overall Deal19.4.2018 13:00 | Pressemelding
(NASDAQ: AMZN)— Amazon Studios announced today that it has greenlit a straight-to-series order for Utopia, a nine-episode series from award-winning Gillian Flynn, the best-selling author and screenwriter of Golden Globe nominated Gone Girl and HBO’s highly anticipated Sharp Objects. Flynn has also inked an overall deal with Amazon Studios across television, marking Utopia as the first project. Utopia will be available exclusively on Prime Video in more than 200 countries and territories. Utopia is based on the British series of the same name written by Dennis Kelly. The series is a co-production between Endemol Shine North America and Kudos, an Endemol Shine Group UK production studio, and Amazon Studios. A group of young adults, who meet online, are mercilessly hunted by a shadowy deep state organization after they come in to possession of a near mythical cult underground graphic novel – they discover the conspiracy theories in the comic’s pages may actually be real and are forced in
Yourtyres.co.uk at The Tire Cologne 2018: Concepts for Linking Online and Offline Business19.4.2018 12:47 | Pressemelding
Delticom AG/Yourtyres.co.uk. At this year’s Tire Cologne trade fair, Yourtyres.co.uk will be presenting its partnership model, which focuses on the linking of online and offline trade. Yourtyres.co.uk is the online wholesale shop from Europe’s largest tyre retailer, Delticom. From 29th May to 1st June, visitors to the fair can learn how workshops and stationary tyre retailers are able to benefit from the increasing amount of online trade without having to give up their independence. This is because Yourtyres.co.uk offers its wholesale customers excellent terms of purchase and high flexibility. There are no minimum purchase levels, and customers are not obliged to stock specific brands. There are also no contract costs or commissions. Using the Yourtyres.co.uk website and placing orders are completely free of charge. Customers benefit from the shop’s wide range of car, truck and motorbike tyres, as well as high availability all year round thanks to Delticom’s in-house warehousing and in
Flowsion A/S Wins Horizon 2020 SME Instrument Grant for Automatic Glucose Control in Intensive Care Medicine19.4.2018 11:48 | Pressemelding
Flowsion, the Denmark-based developer of continuous blood glucose systems for intensive care medicine, has won a prestigious European Commission Horizon 2020 SME Instrument award. The grant was awarded to assist in the development of an innovative automatic blood glucose control system, Glucostat, developed by Flowsion. Glucostat is expected to reduce mortality, morbidity, length of stay and treatment costs dramatically for intensive care patients compared to existing technologies. “It’s a welcome validation of our innovative, patented technology and a confirmation that we are addressing a really significant problem with a globally-relevant market opportunity,” said Hans Jorgen Pedersen, CEO of Flowsion. “Flowsion has already performed clinical studies with the system so we now that Glucostat will fulfil the demands of the intensive care units.” With 5-8 % success rate the European Innovation Council SME Instrument awards are exceptionally competitive, and only 3018 companies across Eu
Nexperia Secures $800M Financing to Fund Future Growth Plans19.4.2018 09:33 | Pressemelding
Nexperia, the global leader in discretes, logic and MOSFET devices, today announced the successful completion of a refinancing of its current facilities with USD 800 million equivalent of senior credit facilities. This includes a significant proportion of Revolving Credit facility. The proceeds will be used to refinance existing outstanding debt and for Capex expenditure to fund future growth. The facilities were arranged by Bank of America Merrill Lynch and HSBC, acting as Global Coordinators, and were syndicated by a group of nine global banks. The refinancing is fully supported by JAC Capital and Wise Road Capital, Nexperia’s two main shareholders, and provides a flexible financing package at very attractive terms to support the further growth of Nexperia going forward. Comments from Frans Scheper, Nexperia’s CEO: “This is the first time that Nexperia has approached the financial markets as an independent company, so we are very pleased with the enthusiastic response. Refinancing th
Grundig – Redefining Kitchen Design and Technology19.4.2018 09:19 | Pressemelding
UNLEASH YOUR GOURMET CAPABILITIES WITH GRUNDIG’S GOURMET CHEF™ OVEN This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180419005580/en/ (Photo: Grundig) Grundig’s Gourmet Chef™ Oven makes cooking elaborate, delicious meals easier than ever before. The oven’s intuitive design and innovative technology combine to simplify cooking and cleaning processes, inspire culinary creativity, and produce exquisite results. Equipped with advanced connected technologies and sensors, it allows users to precisely control the temperature of their food as it cooks to ensure the best results. This includes a high temperature moisture sensor, a temperature control sensor and BLDC motor, an integrated camera and a multipoint meat probe. Cleaning up after your culinary creation couldn’t be easier for users, with the oven fitted with advanced automatic self cleaning, including water and high-pressure steam cleaning, The Gourmet Chef™ elegant and sophis
PIXID Continues European Expansion with Acquisition of Dutch Staffing CRM Supplier Carerix19.4.2018 09:09 | Pressemelding
European workforce management solutions provider PIXID, has acquired Carerix, a Dutch-based CRM and ATS supplier, to further strengthen its proposition and expand its operations. Adding a leading supplier for CRM and ATS systems to its ranks allows PIXID to reinforce its expertise, enhance its service offering and strengthen the value chain offered to the temporary employment sector. The purchase also means PIXID can now add a presence in Benelux to its existing offices in France, in the UK (since its acquisition of The Internet Corporation in 2017) and its operations in Germany. A complete online software solution for recruitment and staffing agencies, Carerix is currently helping more than 10,000 users every day. It has a presence in 17 countries due to high-profile relationships with major customers including Randstad, Adecco, Manpower, T-Groep and DPA. Carerix has a multi-level partnership programme and an ecosystem which allows for a tailored offering and broader promotion of its